Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 16:01 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and...
April 13, 2026 07:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...
April 13, 2026 06:11 ET | Source: Research and Markets

Cell Therapy Technology Market Research and Global Forecast Report 2025-2030: Rising Chronic Disease Burden and CRISPR-Driven Gene Editing Innovations Driving Growth

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Technologies Market by Product, Process, Type, Application - Global Forecast to 2030" has been added to ResearchAndMarkets.com's...
April 08, 2026 09:15 ET | Source: Longeveron

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).
April 07, 2026 10:06 ET | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report, February 2026: Latest Business Conditions, New Outsourcing Contracts, Opportunity Assessment, Threats for Manufacturers, Mergers, Acquisitions, and Financing

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, February 2026" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
April 07, 2026 07:09 ET | Source: Pluristyx, Inc.

Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.
April 03, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response ...
April 02, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
April 01, 2026 07:05 ET | Source: Research and Markets

Automated Cell Processing Systems Market Report 2026-2035: Industry Poised for 16% CAGR Growth Amid Biotechnology Breakthroughs

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of...
March 31, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...